Mundipharma’s Cambridge Science Park facility has long been a recognisable landmark. Designed by renowned Canadian architect Arthur Erickson, the building, affectionately known as the “toast rack, is a distinctive feature visible from the A14.
From some of the earliest days of the Park, the facility has been home to Mundipharma, a global healthcare company, including its associated companies, Bard and Napp. The facility serves as Mundipharma’s global headquarters, where high-quality medicines are manufactured and distributed to make a positive impact on patients around the world.
Why Mundipharma is Growing at Cambridge Science Park
To meet the increasing demand for important medicines, Mundipharma is investing in a major expansion at its Cambridge Science Park facility. This development will strengthen the company’s capabilities and support even more patients and communities worldwide. The plans include:
- Enhanced filling and packing capacity
New filling and packing lines will help Mundipharma deliver medicines more efficiently and reliably. - Specialised manufacturing facility
A new bead-coating facility will enable Mundipharma to meet the growing need for ADHD medications in Canada. - Commitment to sustainability
The expansion plans include the installation of solar PV panels to generate clean energy, reinforcing Mundipharma’s commitment to environmental responsibility, alongside LED lighting providing 75% coverage across the facility. Mundipharma also remains committed to enhancing local biodiversity through the ongoing development of landscaped areas, including the planting of trees and shrubs, and the continued development of natural ponds. These features support a rich variety of wildlife and contribute to the overall quality of the Science Park environment. As part of the expansion, bat and bird boxes will also be installed to further encourage and protect native species.
Looking Ahead
This expansion is more than a building project. It represents Mundipharma’s ongoing commitment to patients, partners, and the local community, ensuring the continued innovation, adaptation, and delivery of medicines that matter most.
For further information, please contact terry.dickinson@napp.co.uk